Guanidinium chloride

Guanidinium chloride
Names
IUPAC name
Carbamimidoylazanium chloride
Other names
Guanidine hydrochloride
Identifiers
50-01-1 YesY
ChEBI CHEBI:32735 YesY
ChemSpider 5540 YesY
Jmol interactive 3D Image
PubChem 10855382
UNII 3YQC9ZY4YB YesY
Properties
CH6ClN3
Molar mass 95.53 g·mol−1
Appearance orthorhombic bipyramidal crystals
Density 1.354 g/cm3 at 20 °C
Melting point 182.3 °C (360.1 °F; 455.4 K)
very soluble in water and ethanol[1]
Hazards
Safety data sheet External MSDS
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
YesY verify (what is YesYN ?)
Infobox references

Guanidinium chloride or guanidine hydrochloride, usually abbreviated GdmCl and sometimes GndCl or GuHCl, is the hydrochloride salt of guanidine.

Structure

Guanidinium chloride crystallizes in orthorhombic space group Pbca. The crystal structure consists of a network of guanidinium cations and chloride anions linked by N–H···Cl hydrogen bonds.[2]

Use in protein denaturation

Guanidinium chloride is a strong chaotrope and one of the strongest denaturants used in physiochemical studies of protein folding. At high concentrations of guanidinium chloride (e.g., 6 M), proteins lose their ordered structure, and they tend to become randomly coiled, i.e. they do not contain any residual structure. However, at concentrations in the millimolar range in vivo, guanidinium chloride has been shown to "cure" prion positive cells (i.e. cells exhibiting a prion positive phenotype revert to a prion negative phenotype). This is the result of inhibition of the Hsp104 chaperone protein known to play an important role in prion fiber fragmentation and propagation.[3][4][5]

Historical survey

Petrunkin and Petrunkin (1927, 1928) appear to be the first who studied the binding of GndCl to gelatin and a mixture of thermally denatured protein from brain extract. Greenstein (1938, 1939), however, appears to be the first to discover the high denaturing action of guanidinium halides and thiocyanates in following the liberation of sulfhydryl groups in ovalbumin and few other proteins as a function of salt concentration.[6]

Medical Uses

Guanidine hydrochloride is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with Eaton-Lambert syndrome. It is not indicated for treating myasthenia gravis. It apparently acts by enhancing the release of acetylcholine following a nerve impulse. It also appears to slow the rates of depolarization and repolarization of muscle cell membranes. Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects. Side effects include increased peristalsis and diarrhea. Fatal bone-marrow suppression, apparently dose related, can occur with guanidine.

References

  1. Lide, David R. (1998). Handbook of Chemistry and Physics (87 ed.). Boca Raton, FL: CRC Press. pp. 3–296. ISBN 0-8493-0594-2.
  2. Haas, D. J.; Harris, D. R.; Mills, H. H. (1965). "The crystal structure of guanidinium chloride". Acta Crystallogr. 19: 676–679. doi:10.1107/S0365110X65004085.
  3. Ferreira PC, Ness F, Edwards SR, Cox BS, Tuite MF (2001) The elimination of the yeast [PSI+] prion by guanidine hydrochloride is the result of Hsp104 inactivation. Mol Microbiol 40 (6):1357-1369.
  4. Ness F, Ferreira P, Cox BS, Tuite MF (2002) Guanidine hydrochloride inhibits the generation of prion "seeds" but not prion protein aggregation in yeast. Mol Cell Biol 22 (15):5593-5605.
  5. Eaglestone SS, Ruddock LW, Cox BS, Tuite MF (2000) Guanidine hydrochloride blocks a critical step in the propagation of the prion-like determinant [PSI(+)] of Saccharomyces cerevisiae. Proc Natl Acad Sci USA 97 (1):240-244.
  6. Lapange, Savo (1978). Physicochemical aspects of protein denaturation. New York: Wiley. ISBN 0-471-03409-6.
This article is issued from Wikipedia - version of the Monday, November 02, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.